Lung Cancer

Five things for pharma marketers to know: Friday, February 24, 2017

Five things for pharma marketers to know: Friday, February 24, 2017

By

PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug

Marketers take a new approach to lung-cancer campaigns, and why that matters

Marketers take a new approach to lung-cancer campaigns, and why that matters

By

Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.

Sales of Keytruda miss analysts' mark

Sales of Keytruda miss analysts' mark

By

Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.

MM&M's 5 most popular stories in September 2016

MM&M's 5 most popular stories in September 2016

By

Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines

Novartis sets out to debunk misconception that only smokers get lung cancer

Novartis sets out to debunk misconception that only smokers get lung cancer

By

Approximately 10% to 15% of lung cancer patients have never smoked and have developed the disease due to genetic alterations.

OPINION

Newsletters